Stuart Woods
Stuart Woods
Verified email at
Cited by
Cited by
Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection
G Lou, G Anderluzzi, ST Schmidt, S Woods, S Gallorini, M Brazzoli, ...
Journal of Controlled Release 325, 370-379, 2020
Immunogenetics of Toxoplasma gondii informs vaccine design
FL Henriquez, S Woods, H Cong, R McLeod, CW Roberts
Trends in parasitology 26 (11), 550-555, 2010
A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: Formulation, cellular uptake and biodistribution investigations
G Lou, G Anderluzzi, S Woods, CW Roberts, Y Perrie
European Journal of Pharmaceutics and Biopharmaceutics 143, 51-60, 2019
Salicylanilide inhibitors of Toxoplasma gondii
A Fomovska, RD Wood, E Mui, JP Dubey, LR Ferreira, MR Hickman, ...
Journal of medicinal chemistry 55 (19), 8375-8391, 2012
New paradigms for understanding and step changes in treating active and chronic, persistent apicomplexan infections
M McPhillie, Y Zhou, K El Bissati, J Dubey, H Lorenzi, M Capper, ...
Scientific reports 6 (1), 29179, 2016
Adjuvanted multi-epitope vaccines protect HLA-A* 11: 01 transgenic mice against Toxoplasma gondii
K El Bissati, AA Chentoufi, PA Krishack, Y Zhou, S Woods, JP Dubey, ...
JCI insight 1 (15), 2016
Parasites lacking the micronemal protein MIC2 are deficient in surface attachment and host cell egress, but remain virulent in vivo
S Gras, A Jackson, S Woods, G Pall, J Whitelaw, JM Leung, GE Ward, ...
Wellcome open research 2, 2017
The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency
G Anderluzzi, G Lou, S Woods, ST Schmidt, S Gallorini, M Brazzoli, ...
Journal of Controlled Release 342, 388-399, 2022
Toxoplasma gondii HLA-B* 0702-restricted GRA720-28 peptide with adjuvants and a universal helper T cell epitope elicits CD8+ T cells producing interferon-γ and reduces parasite …
H Cong, EJ Mui, WH Witola, J Sidney, J Alexander, A Sette, A Maewal, ...
Human Immunology 73 (1), 1-10, 2012
Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes
D Chatzikleanthous, ST Schmidt, G Buffi, I Paciello, R Cunliffe, F Carboni, ...
Journal of Controlled Release 323, 125-137, 2020
Multi-Omics Studies Demonstrate Toxoplasma gondii-Induced Metabolic Reprogramming of Murine Dendritic Cells
KE Hargrave, S Woods, O Millington, S Chalmers, GD Westrop, ...
Frontiers in cellular and infection microbiology 9, 309, 2019
MAP Kinase Phosphatase-2 Plays a Key Role in the Control of Infection with Toxoplasma gondii by Modulating iNOS and Arginase-1 Activities in Mice
S Woods, J Schroeder, HA McGachy, R Plevin, CW Roberts, J Alexander
PLoS pathogens 9 (8), e1003535, 2013
Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase
G Cheng, SP Muench, Y Zhou, GA Afanador, EJ Mui, A Fomovska, BS Lai, ...
Bioorganic & medicinal chemistry letters 23 (7), 2035-2043, 2013
Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments
RV D'Elia, S Woods, W Butcher, J McGahon, S Khadke, Y Perrie, ...
Journal of controlled release 298, 202-212, 2019
Modification of Triclosan Scaffold in Search of Improved Inhibitors for Enoyl‐Acyl Carrier Protein (ACP) Reductase in Toxoplasma gondii
J Stec, A Fomovska, GA Afanador, SP Muench, Y Zhou, BS Lai, ...
ChemMedChem 8 (7), 1138-1160, 2013
Potent tetrahydroquinolone eliminates apicomplexan parasites
MJ McPhillie, Y Zhou, MR Hickman, JA Gordon, CR Weber, Q Li, PJ Lee, ...
Frontiers in cellular and infection microbiology 10, 203, 2020
Acanthamoeba activates macrophages predominantly through Toll-like receptor 4-and MyD88-dependent mechanisms to induce interleukin-12 (IL-12) and IL-6
A Cano, A Mattana, S Woods, FL Henriquez, J Alexander, CW Roberts
Infection and immunity 85 (6), 10.1128/iai. 01054-16, 2017
Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses
G Anderluzzi, ST Schmidt, R Cunliffe, S Woods, CW Roberts, D Veggi, ...
Journal of controlled release 330, 933-944, 2021
Glucosamine-NISV delivers antibody across the blood-brain barrier: Optimization for treatment of encephalitic viruses
S Woods, LM O'Brien, W Butcher, JE Preston, AR Georgian, ...
Journal of Controlled Release 324, 644-656, 2020
T Cell Hypo-Responsiveness against Leishmania major in MAP Kinase Phosphatase (MKP) 2 Deficient C57BL/6 Mice Does Not Alter the Healer Disease Phenotype
J Schroeder, HA McGachy, S Woods, R Plevin, J Alexander
PLoS neglected tropical diseases 7 (2), e2064, 2013
The system can't perform the operation now. Try again later.
Articles 1–20